Home >> Marketplace Directory >> Genomic test service for hematologic malignancies, 6/15

Genomic test service for hematologic malignancies, 6/15

image_pdfCreate PDF

June 2015—LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring, and selection of treatment for myeloid neoplasms is now available from Quest Diagnostics. The lab-developed test uses next-generation sequencing, polymerase chain reaction, and other techniques to interrogate DNA from leukocytes in blood or bone marrow specimens for the presence of mutations in 30 genes most frequently associated with myeloid neoplasms.

For myelodysplastic syndrome, LeukoVantage may detect certain molecular markers to help identify early stages of the disease, complementing conventional diagnostic techniques. For MPN, LeukoVantage may identify molecular markers that can aid the selection of certain targeted therapies, such as JAK2 inhibitors, and in establishing a prognosis.

LeukoVantage has also been shown to detect gene mutations in greater than 95 percent of newly diagnosed cases of AML. Physicians may use this information to aid in disease diagnosis and subclassification as well as to establish a treatment plan with induction chemotherapy. In addition, LeukoVantage may aid in establishing a prognosis and monitoring for minimal residual disease and recurring disease. In the case of both AML and MDS, LeukoVantage may also provide information for selecting epigenetic modifying drugs, which may be less toxic than inpatient chemotherapies.

Quest Diagnostics, 800-222-0446

CAP TODAY
X